These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2841691

  • 1. A substituted thieno[3.4-d]imidazole versus substituted benzimidazoles as H+, K+-ATPase inhibitors.
    Herling AW, Bickel M, Lang HJ, Weidmann K, Rösner M, Metzger H, Rippel R, Nimmesgern H, Scheunemann KH.
    Pharmacology; 1988; 36(5):289-97. PubMed ID: 2841691
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of H+,K+-ATPase by methyl(E)-2-(3,4-dimethoxystyryl)-benzimidazole-4-carboxylate (ALE-36).
    Yamamoto O, Tanaka H, Ueda F, Kimura K.
    Scand J Gastroenterol Suppl; 1989; 162():178-81. PubMed ID: 2556788
    [Abstract] [Full Text] [Related]

  • 7. 2-[(2-pyridylmethyl)sulfinyl]-1H-thieno[3,4-d]imidazoles. A novel class of gastric H+/K(+)-ATPase inhibitors.
    Weidmann K, Herling AW, Lang HJ, Scheunemann KH, Rippel R, Nimmesgern H, Scholl T, Bickel M, Metzger H.
    J Med Chem; 1992 Feb 07; 35(3):438-50. PubMed ID: 1310742
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl)benzimidazole products.
    Beil W, Hannemann H, Mädge S, Sewing KF.
    Eur J Pharmacol; 1987 Jan 06; 133(1):37-45. PubMed ID: 3030771
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
    Fryklund J, Wallmark B.
    J Pharmacol Exp Ther; 1986 Jan 06; 236(1):248-53. PubMed ID: 3001289
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.
    Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, Wallmark B.
    Nature; 1981 Mar 12; 290(5802):159-61. PubMed ID: 6259537
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
    Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N.
    Biochem Pharmacol; 1991 Jul 05; 42(2):321-8. PubMed ID: 1650210
    [Abstract] [Full Text] [Related]

  • 20. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
    Kohl B, Sturm E, Senn-Bilfinger J, Simon WA, Krüger U, Schaefer H, Rainer G, Figala V, Klemm K.
    J Med Chem; 1992 Mar 20; 35(6):1049-57. PubMed ID: 1313110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.